<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00578539</url>
  </required_header>
  <id_info>
    <org_study_id>H-21079-REGALE</org_study_id>
    <secondary_id>REGALE</secondary_id>
    <nct_id>NCT00578539</nct_id>
    <nct_alias>NCT00647010</nct_alias>
  </id_info>
  <brief_title>T-Reg Cell Kinetics, Stem Cell Transplant, REGALE</brief_title>
  <acronym>REGALE</acronym>
  <official_title>T-Regulatory Cell Kinetics for Patients Receiving Alemtuzamb and Undergoing Stem Cell Transplantation From HLA Mismatched-Related, or HLA Matched, or One Antigen Mismatched-Unrelated Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for Cell and Gene Therapy, Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients have a type of blood cell disorder that is very hard to cure. We are now suggesting
      a treatment that might help patients live longer without disease than other treatment plans
      would. This treatment is known as a stem cell transplant. We believe this may help patients
      as it allows us to give much stronger doses of drugs and radiation to kill the diseased cells
      than we could give without the transplant. We also think that the healthy cells may help
      fight any diseased cells left after the transplant.

      Stem Cells are special &quot;mother&quot; cells that are found in the bone marrow (the spongy tissue
      inside bones), although some are also found in the bloodstream (peripheral blood). As they
      grow, they become either white blood cells which fight infection, red blood cells which carry
      oxygen and remove waste products from the organs and tissues or platelets, which enable the
      blood to clot. For the transplant to take place, we will collect these stem cells from a
      &quot;donor&quot; (a person who agrees to donate these cells) and give them to recipient. Patients do
      not have a sibling that is a perfect match, so the stem cells will come from a donor who is
      the best match available. This person may be a close relative or an unrelated person whose
      stem cells best &quot;matches&quot; the patients, and who agrees to donate stem cells. Before the
      transplant, two very strong drugs plus total body irradiation will be given to the patient
      (pre-conditioning). This treatment will kill most of the blood-forming cells in the bone
      marrow. We will then give the patient the healthy stem cells. Once these healthy stem cells
      are in the bloodstream they will move to the bone marrow (graft) and begin producing blood
      cells that will eventually mature into healthy red blood cells, white blood cells and
      platelets.

      This research study will also use CAMPATH-1H as a pre-treatment. CAMPATH-1H is an antibody
      against certain types of blood cells. CAMPATH-1H is important because it stays active in the
      body for a long time after infusion, which means it may work longer at preventing GvHD
      symptoms.

      The stem cell transplant described above is considered to be &quot;standard&quot; treatment. We would
      like to collect additional blood as described below in order to evaluate how the immune
      system is recovering.

      We are asking permission to draw blood from the patient so that we can measure the number of
      certain blood cells called T regulatory cells. T regulatory cells are special immune cells
      that can control or regulate the body's immune response. We want to determine whether T
      regulatory cells are important participants in graft versus host disease (GVHD), infection
      and relapse. In GVHD, certain cells from the donated marrow or blood (the graft) attack the
      body of the transplant patient (the host). GVHD can affect many different parts of the body.
      The skin, eyes, stomach and intestines are affected most often. GVHD can range from mild to
      life-threatening. We do not know whether T regulatory cells can modify these conditions. We
      want to measure these T regulatory cells and learn if these cells do influence these
      conditions. If we learn that T regulatory cells do affect these conditions, then it may be
      possible to modify these cells for the benefit of transplant patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To participate in this transplant, the patient will need to have a central line.

      Before the transplant we will test the blood for viruses which can cause problems after the
      transplant. These viruses include Hepatitis B, cytomegalovirus and HIV. If the patient is
      positive for the AIDS virus, they will not be able to undertake the transplant.

      Standard therapy: The patient will be given 6 doses of chemotherapy with a drug called Ara C
      in high doses (every 12 hours) which will begin 8 days before the stem cell transplant. Then,
      another chemotherapy drug called cyclophosphamide will be given in high doses by vein for two
      days on the 7th and 6th days before the transplant. A drug called MESNA will be given with
      cyclophosphamide. MESNA is used to decrease the side effects caused by cyclophosphamide. The
      patient will also receive an antibody called Campath (each day for 4 days before the
      transplant) to help destroy the immune system so that there is less host resistance to the
      growth of the donor cells. Radiation treatment will be given to the entire body on each day
      for 4 days before transplant. This will be given 2 times a day for 4 days. The chemotherapy
      and radiation treatment will last 8 days. If the patient has a diagnosis of T-cell Lymphoma,
      they will not be given the Ara-C.

      Extra bone marrow tests may be recommended by the physician to check on the patients
      condition, especially if the marrow is slow to grow.

      The day after the radiation treatment is completed; the patient will receive the healthy stem
      cells by vein. Once in the bloodstream, these stem cells will go to the bone marrow and
      should begin to grow.

      In prevention of GvHD, the patient will also receive medicine called FK506 as well as low
      dose methotrexate. The FK506 will be given intravenously initially starting 2 days before the
      transplant and later by mouth (when they are able to take oral medications). This drug will
      be given each day for several weeks. Four doses of low dose methotrexate will be given
      intravenously. The methotrexate will be given on the day after the transplant, 3, 6 and 11
      days after the transplant. If the GVHD cannot be controlled with FK506, other medicines may
      need to be given. The doctor will describe these medicines at that time.

      Blood samples for research: To study how these cells are working in the patients system,
      blood samples will be taken each month for six months, at nine months, at one year, 2 years
      and 3 years following transplant. Approximately 6-8 teaspoons of blood will be collected each
      time. The total blood drawn for this study over three years should not exceed 1 and 3/4 cups.
      This amount is considered safe in adults. The amount of blood collected will be decreased in
      children and/or in patients where this amount of blood collection would not be appropriate.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Percentage of Treg Cells at 1 Year Post Transplant</measure>
    <time_frame>1 year</time_frame>
    <description>To define the biologic recovery and behavior of T regulatory cells for patients undergoing stem cell transplantation as specified in this protocol</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Leukemia</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Non Hodgkin Lymphoma</condition>
  <condition>Myeloproliferative Disorders</condition>
  <arm_group>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive Ara C IV every 12 hours for 6 doses starting at 1400 hours on day -8. Cyclophosphamide IV once daily on day -7 and day -6 starting at 1400 hours. MESNA will be administered 15 minutes prior to each dose of Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide. Campath 1h will be given on day -4, day -3, day -2 and day-1. TBI (Total Body Irradiation) will be delivered in 8 fractions of 1.75 Gy in two fractions on day -4, day -3, day -2, and day -1. Stem cell Infusion are infused on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARA C</intervention_name>
    <description>Ara C (3000 mg/m2) IV every 12 hours for 6 doses (days -8 to -5)</description>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
    <other_name>Cytarabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide (45mg/kg) IV once daily on day -7 and day -6</description>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MESNA</intervention_name>
    <description>MESNA (45mg/kg; divided into 5 doses) will be administered 15 minutes prior to each dose of Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide.</description>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
    <other_name>Mesnex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Irradiation (TBI)</intervention_name>
    <description>TBI: total dose 14.0 Gy, will be delivered in 8 fractions of 1.75 Gy in two fractions on day -4, day -3, day -2, and day -1</description>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
    <other_name>Radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Campath-1h</intervention_name>
    <description>CAMPATH (3 mg IV for patients between 5 and 15 kg; 5 mg for patients between 16 and 30 kg; and 10 mg for patients greater than 30 kg) will be given on day -4, day -3, day -2 and day-1.</description>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
    <other_name>Alemtuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Infusion</intervention_name>
    <description>Stem cells are infused on day 0</description>
    <arm_group_label>Stem Cell Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Patients with acute or chronic leukemia or advanced Hodgkin or non Hodgkin lymphoma or
             myelodysplastic/myeloproliferative disease who are unlikely to be cured by standard
             chemotherapy treatments. This includes patients who have relapsed after standard
             chemotherapy treatments and patients in first remission with unfavorable prognostic
             features.

          -  Using the standard 6 HLA antigen profile (HLA class I, A and B, and HLA class II,
             DRB1) a patient must have either a one HLA antigen mismatched related donor or an HLA
             matched or one antigen mismatched unrelated donor.

        EXCLUSION CRITERIA:

          -  Patients with a life expectancy (less than or equal to 6 weeks) limited by disease
             other than leukemia.

          -  Patients with symptomatic cardiac failure unrelieved by medical therapy or evidence of
             significant cardiac dysfunction by echocardiogram (shortening fraction &lt;20%).

          -  Patients with severe renal disease (i.e., creatinine greater than 3 times normal for
             age).

          -  Patients with pre-existing severe restrictive pulmonary disease (FVC less than 40% of
             predicted).

          -  Patients with severe hepatic disease (direct bilirubin greater than 3 mg/dl or AST
             greater than 500 IU/L).

          -  Patients with severe personality disorder or mental illness.

          -  Patients with severe infection that in the estimation of the principal investigator
             prohibits the use of ablative chemotherapy.

          -  Patients who are documented HIV positive.

          -  Patients with a Karnofsky performance score &lt;70% or Lansky score &lt;50%.

        NOTE: Patients who would be excluded from treatment on this protocol strictly for
        laboratory abnormalities can be included at the principal investigator's discretion after
        consultation with the members of the SCT Policy and Procedures Committee.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Krance, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2007</study_first_posted>
  <results_first_submitted>August 28, 2014</results_first_submitted>
  <results_first_submitted_qc>August 28, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 8, 2014</results_first_posted>
  <last_update_submitted>March 24, 2016</last_update_submitted>
  <last_update_submitted_qc>March 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Robert Krance</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Stem Cell Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Mesna</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Stem Cell Transplant</title>
          <description>All patients will receive Ara C IV every 12 hours for 6 doses starting at 1400 hours on day -8. Cyclophosphamide IV once daily on day -7 and day -6 starting at 1400 hours. MESNA will be administered 15 minutes prior to each dose of Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide. Campath 1h will be given on day -4, day -3, day -2 and day-1. TBI (Total Body Irradiation) will be delivered in 8 fractions of 1.75 Gy in two fractions on day -4, day -3, day -2, and day -1. Stem cell Infusion are infused on day 0.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 24 patients were enrolled on the study and all of them received the conditioning treatment and the transplant.</population>
      <group_list>
        <group group_id="B1">
          <title>Stem Cell Transplant</title>
          <description>All patients will receive stem cell transplantation conditioning, GVHD prevention and stem cell infusion.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.0" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Percentage of Treg Cells at 1 Year Post Transplant</title>
        <description>To define the biologic recovery and behavior of T regulatory cells for patients undergoing stem cell transplantation as specified in this protocol</description>
        <time_frame>1 year</time_frame>
        <population>Only 13 of the 24 patients enrolled were included in this analysis as only 13 patients have Treg values at 1 year.</population>
        <group_list>
          <group group_id="O1">
            <title>Stem Cell Transplant</title>
            <description>All patients will receive Ara C IV every 12 hours for 6 doses starting at 1400 hours on day -8. Cyclophosphamide IV once daily on day -7 and day -6 starting at 1400 hours. MESNA will be administered 15 minutes prior to each dose of Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide. Campath 1h will be given on day -4, day -3, day -2 and day-1. TBI (Total Body Irradiation) will be delivered in 8 fractions of 1.75 Gy in two fractions on day -4, day -3, day -2, and day -1. Stem cell Infusion are infused on day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Percentage of Treg Cells at 1 Year Post Transplant</title>
          <description>To define the biologic recovery and behavior of T regulatory cells for patients undergoing stem cell transplantation as specified in this protocol</description>
          <population>Only 13 of the 24 patients enrolled were included in this analysis as only 13 patients have Treg values at 1 year.</population>
          <units>percentage of total CD4+ cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="4.6" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Stem Cell Transplant</title>
          <description>All patients will receive Ara C IV every 12 hours for 6 doses starting at 1400 hours on day -8. Cyclophosphamide IV once daily on day -7 and day -6 starting at 1400 hours. MESNA will be administered 15 minutes prior to each dose of Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide. Campath 1h will be given on day -4, day -3, day -2 and day-1. TBI (Total Body Irradiation) will be delivered in 8 fractions of 1.75 Gy in two fractions on day -4, day -3, day -2, and day -1. Stem cell Infusion are infused on day 0.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemolysis (e.g., immune hemolytic anemia, drug-related hemolysis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiopulmonary arrest, cause unknown (non-fatal)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pericardial effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Death not associated with CTCAE term - Multi-organ failure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver dysfunction/failure (clinical)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils - Bladder (urinary)</sub_title>
                <description>Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L) - Bladder (urinary)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils - Blood</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils - Bronchus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils - Lung (pneumonia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils - Urinary tract NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infection - Other: Multiple viral infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infection - Other: Probable fungal disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Abdomen NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Bladder (urinary)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Blood</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Catheter-related</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Upper aerodigestive NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Upper airway NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Urinary tract NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <description>SGOT: serum glutamic oxaloacetic transaminase</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurology - Other: Aseptic meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neurology - Other: Cranial nerve VI palsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neurology - Other: Peripheral neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory - Bronchopulmonary NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other: Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other: Respiratory distress: dyspnea + hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other: Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular - Other: Vaso Oclusive Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam)</sub_title>
                <description>Two events were specified as oral cavity</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other: CMV viremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infection with Grade 3 or 4 neutrophils - Blood</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <description>SGOT: serum glutamic oxaloacetic transaminase</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>PTT</sub_title>
                <description>PTT: Partial Thromboplastin Time</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Krance, MD</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>832-824-4661</phone>
      <email>rakrance@txch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

